Search

Displaying results 9001 - 9010 of 10000 in total
  1. Drug

    ENB-003

    go.drugbank.com/drugs/DB17340
    Investigational

    ENB-003 is a selective and potent inhibitor of the endothelin B receptor (ETBR) being investigated for cancer.

  2. Drug

    MRT5005

    go.drugbank.com/drugs/DB18260
    Investigational

    MRT5005 is a human cystic fibrosis transmembrane conductance regulator (hCFTR) messenger RNA (mRNA) complexed with branched polyethyleneimine (bPEI).

  3. Drug

    TCB-008

    go.drugbank.com/drugs/DB18352
    Investigational

    TCB-008 is an Allogeneic CD3+ T lymphocyte ex vivo expanded expressing the gamma delta T-cell receptor.

  4. Drug

    FLT190

    go.drugbank.com/drugs/DB18420
    Investigational

    FLT190 is a recombinant adeno-associated viral vector serotype S3 containing DNA encoding for human alpha-galactosidase A.

  5. Drug

    Prizloncabtagene autoleucel

    go.drugbank.com/drugs/DB18623
    Investigational

    C-CAR039 is an autologous Chimeric Antigen Receptors (CAR) T-cell therapy expressing CD19/CD20 bi-specific CAR.

  6. Drug

    CTX120

    go.drugbank.com/drugs/DB18625
    Investigational

    CTX120 is an allogeneic CRISPR/Cas9-mediated genetically modified CAR T cell therapy targeting B-cell maturation antigen.

  7. Drug

    Avoplacel

    go.drugbank.com/drugs/DB18659
    Investigational

    Avoplacel (PLX-R18) is an allogeneic cell therapy under investigation for the treatment of acute radiation syndrome.[L48370]

  8. Drug

    Venanprubart

    go.drugbank.com/drugs/DB18891
    Investigational

    Venanprubart is under investigation in clinical trial NCT05781451 (Anti-btla Agonist Therapy in Subjects With Primary Sjogren's Syndrome).

  9. Drug

    BMS-770767

    go.drugbank.com/drugs/DB18902
    Investigational

    BMS-770767 is under investigation in clinical trial NCT01058083 (Safety Study of BMS-770767 in Subjects With Hypercholesterolemia).

  10. Drug

    Edecesertib

    go.drugbank.com/drugs/DB18917
    Investigational

    Edecesertib is under investigation in clinical trial NCT05629208 (Study of Edecesertib in Participants With Cutaneous Lupus Erythematosus (CLE)).